Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Current Leases for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 21.74% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2025, up 21.74%, and an annual FY2025 reading of $2.4 million, up 21.74% over the prior year.
  • Current Leases was $2.4 million for Q4 2025 at Keros Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.4 million in Q4 2025 and bottomed at $436000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.2 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Current Leases tumbled 47.22% in 2022, then skyrocketed 203.93% in 2024.
  • Year by year, Current Leases stood at $862000.0 in 2021, then crashed by 47.22% to $455000.0 in 2022, then soared by 120.88% to $1.0 million in 2023, then surged by 96.82% to $2.0 million in 2024, then rose by 21.74% to $2.4 million in 2025.
  • Business Quant data shows Current Leases for KROS at $2.4 million in Q4 2025, $2.3 million in Q3 2025, and $2.2 million in Q2 2025.